- VBI Vaccines (VBIV +1.2%) and Syneos Health (SYNH -0.8%)have entered into commercialization partnership for the VBI’s 3-antigen prophylactic hepatitis B (HBV) vaccine in the U.S., Europe, and Canada, pending regulatory approvals.
- VBI and Syneos Health have been working together on the pre-launch strategy and activity since Q4 of 2019, and the companies have expanded their relationship to build the leadership team and field teams and incorporate full service commercialization solutions.
- U.S marketing application was submitted on November 30 and European application was filed on 23 November.
- https://seekingalpha.com/news/3642235-vbi-vaccines-recruits-syneos-health-commercialization-partner-for-hbv-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.